We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies.
- Authors
Tuan Vu, Trung; Clapham, Hannah; Huynh, Van Thi Thuy; Vo Thi, Long; Le Thi, Dui; Vu, Nhu Tuyet; Nguyen, Giang Thi; Huynh, Trang Thi Xuan; Duong, Kien Thi Hue; Tran, Vi Thuy; Huynh, Huy Le Anh; Le Huynh, Duyen Thi; Huynh, Thuy Le Phuong; Nguyen, Thuy Thi Van; Nguyen, Nguyet Minh; Luong, Tai Thi Hue; Phong, Nguyen Thanh; Nguyen, Chau Van Vinh; Gough, Gerald; Wills, Bridget
- Abstract
Dengue is the most prevalent arboviral disease of humans. Virus neutralizing antibodies are likely to be critical for clinical immunity after vaccination or natural infection. A number of human monoclonal antibodies (mAbs) have previously been characterized as able to neutralize the infectivity of dengue virus (DENV) for mammalian cells in cell-culture systems. We tested the capacity of 12 human mAbs, each of which had previously been shown to neutralize DENV in cell-culture systems, to abrogate the infectiousness of dengue patient viremic blood for mosquitoes. Seven of the twelve mAbs (1F4, 14c10, 2D22, 1L12, 5J7, 747(4)B7, 753(3)C10), almost all of which target quaternary epitopes, inhibited DENV infection of Ae. aegypti. The mAbs 14c10, 747(4)B7 and 753(3)C10 could all inhibit transmission of DENV in low microgram per mL concentrations. An Fc-disabled variant of 14c10 was as potent as its parent mAb. The results demonstrate that mAbs can neutralize infectious DENV derived from infected human cells, in the matrix of human blood. Coupled with previous evidence of their ability to prevent DENV infection of mammalian cells, such mAbs could be considered attractive antibody classes to elicit with dengue vaccines, or alternatively, for consideration as therapeutic candidates. Dengue is the most prevalent arboviral disease affecting humans. There are no therapeutics for the disease. We developed a novel virus neutralization assay, employing Ae. aegypti mosquitoes and viremic blood from dengue patients, to examine the virus-neutralizing potency of 12 human-derived monoclonal antibodies (mAbs) that had previously been shown to neutralize DENV in cell-culture systems. Five of the twelve mAbs failed to block dengue virus infections of mosquitoes using our assay. The remaining seven mAbs neutralized at least one serotype of dengue virus. The results demonstrate that some mAbs were functional and potently neutralized DENV in the complex matrix of viremic human blood. These findings advance the understanding of the types of antibodies that would be desirable to elicit using a dengue vaccine or to apply for acute therapy.
- Subjects
DENGUE viruses; AEDES aegypti; MONOCLONAL antibodies; VIRAL transmission; ARBOVIRUS diseases
- Publication
PLoS Neglected Tropical Diseases, 2019, Vol 13, Issue 11, p1
- ISSN
1935-2727
- Publication type
Article
- DOI
10.1371/journal.pntd.0007142